We have been selected as a Top Innovator and Featured Presenter at the New England Venture Summit (NEVS) held in Boston next week (December 10-11, 2024). NEVS is a premier event showcasing groundbreaking innovation and providing networking opportunities with industry executives. This event will highlight our development program’s key differentiators and facilitate meetings with industry partners who are focused on accelerating the progress of innovative therapeutic technologies towards commercial viability.
We continue to see pharma increasing efforts in sourcing deals for pre-clinical tumor targeting platforms. We are well-positioned for these early pharma partnerships, and we hope that you will join our journey towards an early exit and expedite novel therapies for patients.
About CEO Jonthan Aramubla, InnovoTEX’s Featured Presenter
Our very own Jonathan Arambula will be presenting InnovoTEX as a Top Innovator at this year’s NEVS. Dr. Arambula has 15+ years of industry experience, previously serving in various roles such as VP Research and CSO of other successful ventures in which he was a co-founder. As an entrepreneur scientist, he is focused on translational therapies from inception to commercialization and is currently developing the macrocycle drug conjugate (MDC) discovery and development platform at InnovoTEX. Prior to industry, he served as an Assistant Professor of Chemistry at Georgia Southern University and received training as an American Cancer Society Postdoctoral Fellow at the University of Texas at Austin and MD Anderson Cancer Center. Dr. Arambula received his Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign. He is a co-author and co-inventor multiple peer-reviewed publications, issued patents and patent applications involving cancer drug discovery and development. Dr. Arambula is a co-inventor NOVO-111 and other MDCs.